ANI Pharmaceuticals $316.25 million convertible notes offering
We advised ANI Pharmaceuticals on the offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Penumbra $100 million accelerated share repurchase
We advised Penumbra on the ASR transaction
Walgreens Boots Alliance $750 million notes offering
We advised Walgreens Boots Alliance on its debt offering
CytomX Therapeutics $58.3 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Precigen $34 million follow-on offering
We advised Precigen on the SEC-registered offering
Generation Bio $237 million at-the-market offering
The shares are listed on Nasdaq
Bansk Group $1.5 billion going-private acquisition of PetIQ
We are advising Bansk Group on the transaction
Revolution Medicines $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
AC Immune $80 million at-the-market offering
We advised AC Immune on the offering
Clariane €92 million reserved capital increase and €237 million rights offering
We advised Clariane on its refinancing transactions